Takuya Takeichi1, Kazumitsu Sugiura2, Toshifumi Nomura3, Taiko Sakamoto4, Yasushi Ogawa2, Naoki Oiso5, Yuko Futei6, Aki Fujisaki7, Akiko Koizumi8, Yumi Aoyama9, Kimiko Nakajima10, Yutaka Hatano11, Kei Hayashi12, Akemi Ishida-Yamamoto12, Sakuhei Fujiwara11, Shigetoshi Sano10, Keiji Iwatsuki13, Akira Kawada5, Yasushi Suga14, Hiroshi Shimizu3, John A McGrath15, Masashi Akiyama2. 1. Department of Dermatology, Nagoya University Graduate School of Medicine, Nagoya, Japan2St John's Institute of Dermatology, King's College London, Guy's Hospital, London, England. 2. Department of Dermatology, Nagoya University Graduate School of Medicine, Nagoya, Japan. 3. Department of Dermatology, Hokkaido University Graduate School of Medicine, Sapporo, Japan. 4. Sakamoto Clinic, Fujieda, Japan. 5. Faculty of Medicine, Department of Dermatology, Kinki University, Osaka-Sayama, Japan. 6. Division of Dermatology, Ogikubo Hospital, Tokyo, Japan. 7. Department of Dermatology, Fujisaki Hospital, Saga, Japan. 8. Joy Dermatological Clinic, Yamaguchi, Japan. 9. Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan10Department of Dermatology, Kawasaki Hospital, Kawasaki Medical School, Okayama, Japan. 10. Department of Dermatology, Kochi Medical School, Kochi University, Nankoku, Japan. 11. Department of Dermatology, Faculty of Medicine, Oita University, Yufu, Japan. 12. Department of Dermatology, Asahikawa Medical University, Asahikawa, Japan. 13. Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan. 14. Department of Dermatology, Juntendo University Urayasu Hospital, Urayasu, Japan. 15. St John's Institute of Dermatology, King's College London, Guy's Hospital, London, England.
Abstract
Importance: We found CARD14 mutations (2 de novo novel mutations and another previously reported mutation) in 3 of 3 patients with pityriasis rubra pilaris (PRP) type V, but not in patients with PRP of other types. Our findings, combined with the published literature, suggest that type V PRP, both familial and sporadic, can be caused by CARD14 mutations. Detailed clinical observation revealed that all 3 patients displayed unique patchy macular brown hyperpigmentation. Objective: To further determine how often patients with PRP have pathogenic mutations in CARD14 and to elucidate which clinical subtype of PRP is caused by CARD14 mutations. Design, Setting, and Participants: We sequenced the entire coding regions of CARD14 in genomic DNA from patients with 5 clinical subtypes of PRP. The detailed clinical features were analyzed in all the patients. The pathogenicity of each mutation was evaluated by several computational predictions. PRP was classified into 6 subgroups, types I to VI, based on clinical criteria. We categorized all the patients with PRP into the clinical subtypes using the classic PRP classification; 22 cases of PRP with varying subtypes were studied. Main Outcomes and Measures: The prevalence of CARD14 mutations in each subtype of PRP was evaluated. Clinical features and characteristics of patients with PRP with CARD14 mutations were analyzed. Results: Overall 22 patients with PRP were included in our study (12 men, 10 women; mean [SD] age, 26 [18] years). Among 3 patients with PRP type V, all were found to have CARD14 mutations: 2 de novo novel mutations (p.Cys127Ser and p.Gln136Leu), and another previously reported mutation (p.Gly117Ser). All were close to the reported pathogenic domains. In silico analysis of all 3 mutations suggested that they are functionally relevant to pathogenesis. All 3 patients displayed unique patchy macular brown hyperpigmentation additionally to other typical features of PRP. Patients with PRP type I and type IV, 1 patient each, had the rare variants in CARD14. Conclusions and Relevance: Pityriasis rubra pilaris type V is a distinct variant of PRP that is caused by CARD14 mutations. In addition, a rare variant of CARD14 might also be implicated in the pathophysiology of other forms of PRP.
Importance: We found CARD14 mutations (2 de novo novel mutations and another previously reported mutation) in 3 of 3 patients with pityriasis rubra pilaris (PRP) type V, but not in patients with PRP of other types. Our findings, combined with the published literature, suggest that type V PRP, both familial and sporadic, can be caused by CARD14 mutations. Detailed clinical observation revealed that all 3 patients displayed unique patchy macular brown hyperpigmentation. Objective: To further determine how often patients with PRP have pathogenic mutations in CARD14 and to elucidate which clinical subtype of PRP is caused by CARD14 mutations. Design, Setting, and Participants: We sequenced the entire coding regions of CARD14 in genomic DNA from patients with 5 clinical subtypes of PRP. The detailed clinical features were analyzed in all the patients. The pathogenicity of each mutation was evaluated by several computational predictions. PRP was classified into 6 subgroups, types I to VI, based on clinical criteria. We categorized all the patients with PRP into the clinical subtypes using the classic PRP classification; 22 cases of PRP with varying subtypes were studied. Main Outcomes and Measures: The prevalence of CARD14 mutations in each subtype of PRP was evaluated. Clinical features and characteristics of patients with PRP with CARD14 mutations were analyzed. Results: Overall 22 patients with PRP were included in our study (12 men, 10 women; mean [SD] age, 26 [18] years). Among 3 patients with PRP type V, all were found to have CARD14 mutations: 2 de novo novel mutations (p.Cys127Ser and p.Gln136Leu), and another previously reported mutation (p.Gly117Ser). All were close to the reported pathogenic domains. In silico analysis of all 3 mutations suggested that they are functionally relevant to pathogenesis. All 3 patients displayed unique patchy macular brown hyperpigmentation additionally to other typical features of PRP. Patients with PRP type I and type IV, 1 patient each, had the rare variants in CARD14. Conclusions and Relevance: Pityriasis rubra pilaris type V is a distinct variant of PRP that is caused by CARD14 mutations. In addition, a rare variant of CARD14 might also be implicated in the pathophysiology of other forms of PRP.
Authors: A K Dewan; L Sowerby; S Jadeja; C Lian; P Wen; J R Brown; D C Fisher; N R LeBoeuf Journal: Clin Exp Dermatol Date: 2018-05-30 Impact factor: 3.470
Authors: Cindy P Frare; Alli J Blumstein; Amy S Paller; Lia Pieretti; Keith A Choate; Anne M Bowcock; Margarita Larralde Journal: Pediatr Dermatol Date: 2021-08-26 Impact factor: 1.997